Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma. | BMC Cancer | 2024 | 38262966 | PubTator, text mining | PubMed |
| Isocorydine Exerts Anticancer Activity by Disrupting the Energy Metabolism and Filamentous Actin Structures of Oral Squamous Carcinoma Cells. | Curr Issues Mol Biol | 2024 | 38248344 | PubTator, text mining | PubMed |
| Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly. | Nat Commun | 2024 | 38245532 | PubTator, text mining | PubMed |
| NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma. | Cell Commun Signal | 2024 | 38233839 | PubTator, text mining | PubMed |
n6-methyladenosine-modified circular RNA family with sequence similarity 126, member A affects cholesterol synthesis and malignant progression of prostate cancer cells by targeting microRNA-505-3p to mediate calnexin. | J Cancer | 2024 | 38230215 | PubTator, text mining | PubMed |
| Development of an m6A-Related lncRNAs Signature Predicts Tumor Stemness and Prognosis for Low-Grade Glioma Patients. | Stem Cells Int | 2024 | 38229597 | PubTator, text mining | PubMed |
| Relationship between long non-coding RNAs and Hippo signaling pathway in gastrointestinal cancers; molecular mechanisms and clinical significance. | Heliyon | 2024 | 38226210 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p/MAPK1 axis. | Cancer Lett | 2024 | 38211649 | PubTator, text mining | PubMed |
| Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis. | Int J Mol Sci | 2024 | 38203769 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications. | Heliyon | 2024 | 38192819 | PubTator, text mining | PubMed |
| LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma. | Cell Death Dis | 2024 | 38177154 | PubTator, text mining | PubMed |
| Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. | Cell Death Dis | 2024 | 38177102 | PubTator, text mining | PubMed |
| Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. | Eur J Med Res | 2024 | 38173044 | PubTator, text mining | PubMed |
| PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking. | J Transl Med | 2024 | 38169393 | PubTator, text mining | PubMed |
| M6A plays a potential role in carotid atherosclerosis by modulating immune cell modification and regulating aging-related genes. | Sci Rep | 2024 | 38168909 | PubTator, text mining | PubMed |
| Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. | Nat Commun | 2024 | 38167409 | PubTator, text mining | PubMed |
| LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p/SPP1 axis as a ceRNA. | Cancer Cell Int | 2024 | 38167126 | PubTator, text mining | PubMed |
| The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target. | BMC Cancer | 2024 | 38166703 | PubTator, text mining | PubMed |
| The role of TNC in atherosclerosis and drug development opportunities. | Int J Biol Sci | 2024 | 38164188 | PubTator, text mining | PubMed |
| BIRC5 facilitates cisplatin-chemoresistance in a m6A-dependent manner in ovarian cancer. | Cancer Med | 2024 | 38112021 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=21